SCHEMBL3770883

SCHEMBL3770883

CCN1CC2C(CNCc3ccc(F)c(Cl)c3)C2C1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 1/20 0.38
WDR77 Q9BQA1 1/20 0.38
SLC6A9 P48067 3/20 0.37
KCNH2 Q12809 3/20 0.37
CXCR4 P61073 3/20 0.37
SIGMAR1 Q99720 2/20 0.35
CNR2 P34972 1/20 0.35
HTR2A P28223 1/20 0.35
GRM2 Q14416 1/20 0.35
IDO1 P14902 1/20 0.35
DRD4 P21917 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
HDAC3 O15379 2/20 0.34
HDAC1 Q13547 2/20 0.34
HDAC2 Q92769 2/20 0.34
HDAC6 Q9UBN7 2/20 0.34
P2RX7 Q99572 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3783254 0.88 PRMT5 (0.49) PRMT5WDR77SIGMAR1CYP1A2CYP2D6
SCHEMBL3765926 0.87 SLC6A9 (0.47) PRMT5WDR77SLC6A9KCNH2CXCR4
SCHEMBL3771852 0.84 SLC6A9 (0.42) PRMT5WDR77SLC6A9KCNH2CXCR4
SCHEMBL3773846 0.83 P2RX7 (0.47) SLC6A9KCNH2DRD4CYP2D6P2RX7
SCHEMBL713075 0.82 CXCR4 (0.50) SLC6A9CXCR4SIGMAR1CYP1A2CYP2D6
SCHEMBL3777733 0.82 PRMT5 (0.41) PRMT5WDR77SLC6A9KCNH2CXCR4
SCHEMBL15967384 0.81 CACNA1H (0.41) SLC6A9KCNH2CXCR4HDAC3HDAC1
Hydrochloric Acid SCHEMBL711026 0.80 CACNA1H (0.40) SLC6A9CXCR4HDAC3HDAC1HDAC2
SCHEMBL15967241 0.79 PRMT5 (0.47) PRMT5WDR77SLC6A9KCNH2CNR2
Hydrochloric Acid SCHEMBL709865 0.78 PRMT5 (0.46) PRMT5WDR77SLC6A9KCNH2CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1869019-B1 BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS PFIZER PROD INC (US) 2014-08-27 EP claimed
EP-1869019-A1 BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS Pfizer Products Incorporated (US) 2007-12-26 EP claimed
WO-2006106425-A1 BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS PFIZER PRODUCTS INC. (US) 2006-10-12 WO claimed
EP-1869019-B1 BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS PFIZER PROD INC (US) 2014-08-27 EP disclosed
US-20100324020-A1 Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors PFIZER INC. 2010-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324020-A1 Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors SLC1A2, SLC1A1, SLC6A5 PRMT5 900/4885WDR77 1586/4885SLC6A9 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.